Tag: Humacyte
European aXess data: a step forward in an evolving field
Considering the impact of the latest data on a biosynthetic graft for haemodialysis, Bart Dolmatch (Palo Alto, USA) is optimistic but keen to see...
Humacyte’s ATEV achieves superiority versus AV fistula in female dialysis access...
Humacyte has announced positive topline interim results for the V012 Phase 3 study of the acellular tissue engineered vessel (ATEV) in female patients for...
Humacyte ATEV meets primary endpoints in V007 Phase 3 clinical trial...
Humacyte has announced positive top-line results from the V007 Phase 3 clinical trial of the acellular tissue engineered vessel (ATEV) in arteriovenous access for...
Data on Humacyte human acellular vessel published
Humacyte, a clinical-stage biotechnology platform company developing "universally implantable, bioengineered human tissue at commercial scale", has announced in a press release the publication of...
A raft of new directions for vascular access grafts
A departure from the “extreme mantra” of Fistula First unlocks the door to a new, dynamic vision that could swing the pendulum back to...
Bright future for access grafts highlighted at VASBI 2021 with multiple...
New technologies intended to improve the often-mixed outcomes associated with arteriovenous grafts (AVGs) for haemodialysis access were on display at this year’s Vascular Access...
Humacyte to present long-term follow-up data from Phase 2 vascular access...
Humacyte has announced that the clinical results of five-year outcomes in patients receiving the human acellular vessels (HAV) for arteriovenous (AV) access in haemodialysis...